key: cord-0903924-fh1yo6pj authors: Xiao, Chanchan; Qiu, Congling; Deng, Jieping; Ye, Jiezhou; Gao, Lijuan; Su, Jun; Luo, Oscar Junhong; Wang, Pengcheng; Chen, Guobing title: Optimization of antigen specific CD8+ T cell activation conditions for infectious diseases including COVID-19 date: 2021-08-14 journal: STAR Protoc DOI: 10.1016/j.xpro.2021.100789 sha: 5887b5caec25f07d1930bf4df2f594368110b9a0 doc_id: 903924 cord_uid: fh1yo6pj Here, we describe the use of the artificial antigen presenting cell (aAPC) system for the verification of T cell epitopes. We purify and activate CD8+ T cells from blood samples from HLA-A2 that are negative for SARS-CoV-2. CD8+ T cells are combined with peptide-loaded T2-A2 cells, which are then stained with a SARS-CoV-2 specific MHC-1 tetramer to identify specific HLA-A2 restricted T cell epitopes. The use of aAPC and healthy donors means that only BSL2 lab conditions are needed. Here, we describe the use of the artificial antigen presenting cell (aAPC) system for the verification of T cell epitopes. We purify and activate CD8 + T cells from blood samples from HLA-A2 that are negative for SARS-CoV-2. CD8 + T cells are combined with peptide-loaded T2-A2 cells, which are then stained with a SARS-CoV-2 specific MHC-1 tetramer to identify specific HLA-A2 restricted T cell epitopes. The use of aAPC and healthy donors means that only BSL2 lab conditions are needed. For details of the use and implementation of this protocol, please refer to Deng et al.(2021) . This protocol describes to use of the artificial antigen presenting cell (aAPC) system for the verification of T cell epitopes without the need of a high-level biosafety laboratory. T2 is deficient in antigen polypeptide transporter, but overexpresses HLA-A2; thus the cell line is called T2-A2. We selected T2-A2 cell line for the following reasons. First, the inherent deficiency of endogenous antigen presentation made it more reliable to evaluate the presentation of exogenous epitopes by HLA-A2, without the interference from endogenous epitopes. Second, it showed an excellent capability to activate CD8 + T cells, inducing the generation of a high percentage of antigen-specific CD8 + T cells after the primary immune challenge. Third, it could also be used as a target cell for cytotoxicity assessment of activated CD8 + T cells when loaded with given epitopes. The timeline for the overall experimental procedure is shown in Figure 1 . This work was approved by the Institutional Review Board of the Affiliated Huaqiao Hospital of Jinan University. The unexposed donors were healthy people registered in Guangzhou Blood Center and were confirmed negative for SARS-CoV-2 RT-PCR assay. These donors had no known history of any significant systemic diseases, including, but not limited to, hepatitis B or C, HIV, diabetes, kidney or liver diseases, malignant tumors, or autoimmune diseases. All subjects had informed consent that their samples would be used in this study. The HLA-A2 + donors were identified by using flow cytometry. The candidate peptides were synthesized in GenScript Biotechnology Co., Ltd (Nanjing, China) and dissolved in DMSO or in water with the stock concentration at 10 mM (Table 1) . Critical: For preparing peptide solutions, it is recommended to first dissolve the peptide in a minimal amount of solvent (e.g. 1 mL water for 1 mg peptide if the peptide solubility is 1 mg /mL) and then re-adjust the solution with medium for T2-A2 cells buffer. Critical: Peptides containing methionine (M), cysteine (C) or tryptophan (W) are sensitive to DMSO oxidation, and aqueous-based solvent should be used. It is best to aliquote the peptides into appropriate volume (10 µL) per tube for storage. Critical: It is recommended to resuspend peptides in DMSO immediately before use or stored at -20°C (or preferably -80°C). Critical: Please note that distinct dissolution behaviors may happen for small amounts and large amounts of gross peptide in the same solvent. Generally, it takes longer for larger amounts of peptide to dissolve. A brief incubation at warm temperatures (< 40°C ) or sonication can assist in dissolving the peptide. ORF1ab 01 1000 1008 9 TTIQTIVEV 02 1707 1716 10 AANFCALILA 03 2225 2234 10 KLINIIIWFL 04 2230 2238 9 IIWFLLLSV 05 3673 3683 11 SLSGFKLKDCV 06 3672 3683 12 TSLSGFKLKDCV Spike 07 62 70 9 VTWFHAIHV 08 136 145 10 CNDPFLGVYY 09 495 503 9 YGFQPTNGV 10 567 576 10 RDIADTTDAV 11 673 684 12 SYQTQTNSPRRA 12 713 722 10 AIPTNFTISV 13 976 984 9 VLNDILSRL 14 1114 1122 9 IITTDNTFV ORF8 15 73 81 9 YIDIGNYTV 16 18 27 10 QECSLQSCTQ 17 50 58 9 GARKSAPLI N 18 1 9 9 MSDNGPQNQ 19 228 236 9 NQLESKMSG To generate MHC/peptide monomers containing candidate peptides, conditional Flex-T™ monomers were mixed with the desired peptides, which could replace the UV-sensitive peptide through the UV-induced peptide exchange. These new MHC/peptide monomers are then polymerized with streptavidin-fluorophore conjugates, which can subsequently be applied to antigen-specific T cell staining and flow cytometry analysis. Chart protocol ( Figure 2) J o u r n a l P r e -p r o o f GenScript Customized SARS-CoV-2 S136-145 CNDPFLGVYY peptide GenScript Customized SARS-CoV-2 S495-503 YGFQPTNGV peptide GenScript Customized SARS-CoV-2 S567-576 RDIADTTDAV peptide GenScript Customized SARS-CoV-2 S673-684 SYQTQTNSPRRA peptide GenScript Customized SARS-CoV-2 S713-722 AIPTNFTISV peptide GenScript Customized SARS-CoV-2 S S976-984 VLNDILSRL peptide GenScript Customized SARS-CoV-2 S1114-1122 IITTDNTFV peptide Step-by-step method details Note: If the same samples are used for both red blood cell (RBC) lysis and PBMCs isolation, the samples should be divided into 2 aliquots. The volumes depend on the amount of the starting material and ought to be adjusted to meet the requirement for next experiments. Time: 25 minutes In this section, procedures for RBC lysis is described. RBC lysis is performed in whole blood samples from healthy volunteers prior to identification of HLA-A2 by using flow cytometry. Critical: RBC lysis and buffer -Sterilized by filtration through 0.22 μm filter. 1. Prepare the RBC lysis solution 2. RBC lysis a. Manipulate the blood tube in the biological hood, and gently transfer 1 mL blood (About 1 × 10 6 PMBCs) to a 15 mL microcentrifuge tube b. Add 10 mL RBC lysis buffer carefully by using a serological pipette c. Vortex the microcentrifuge tube briefly and put it still for 10 minutes at 25°C d. Centrifuge the cell suspension at 300 × g for 5 minutes at 4°C e. Discard the supernatant and add 15 mL BSM buffer, repeat centrifugation as in step d f. Discard the supernatant and resuspend cells in 100 μL BSM buffer g. Count viable cells and adjust to 5-10 × 10 6 cells/mL with BSM buffer, and distribute cell suspension into 1.5 mL microcentrifuge tubes with 100 µL/tube (5-10 ×10 5 cells/tube, at least 2 tubes) Time: 1 hour In this section, the procedures from PBMCs isolation from whole blood of healthy volunteers is described. These healthy volunteers enrolled in Guangzhou Blood Center and confirmed with a negative report for SARS-CoV-2 RNA real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay. These donors had no known history of any significant systemic diseases, including, but not limited to, hepatitis B or C, HIV, diabetes, kidney or liver diseases, malignant tumors, or autoimmune diseases. The average yield of whole blood per mL was 1-2 × 10 6 cells PBMCs. Lymphocyte Separation Medium (LSM) is designed for the rapid, simple isolation of lymphocytes from diluted defibrinated whole blood layered on a solution of Ficoll ® and centrifuged at low speed (805 × g) for 20 minutes. Blood cells migrate through the solution during centrifugation to form density-specific layers. Lymphocytes and other mononuclear cells form a unique band between LSM fractions and the plasma ( Figure 3A ). Lymphocytes are retrieved by aspirating the plasma layer and then removing the cells. Excess plasma, platelets, and LSM can then be removed by cell washing. To achieve the best J o u r n a l P r e -p r o o f results, use blood drawn within two hours. Blood drawn more than 24 hours before should not be used. Critical: Avoid mixing of density phases to prevent the contamination from red blood cells and granulocytes. f. Wash cells twice with 10 mL PBS by centrifugation at 300 × g for 10 minutes at 4°C Note: Washing the cells removes LSM and decreases the amount of platelets. g. Discard supernatant and resuspend the PBMCs (1 × 10 6 cells/mL) in the desired volume of primary T cell medium In the present section, the procedures for long-term storage of PBMCs for T cell activation later are described. Cells are resuspended in cell freezing medium containing DMSO and stored in liquid nitrogen. In this section, high purity CD8 + T cells are isolated from fresh or frozen human PBMCs by immunomagnetic negative selection. Non-CD8 + T cells are recognized by antibodies specific to their cell surface markers, and labeled with magnetic beads, which help to remove these cells by using an EasySep™magnet. Starting with a single cell suspension of human PBMCs, the CD8 + T cell content of the isolated fraction is typically 98.6% ( Figure 3B ). The wanted CD8 + T cells are then transferred into a new tube, and can be used immediately for downstream applications such as culture and flow cytometry. Note: Yield of CD8 + T cell isolation can greatly vary depending if they are isolated from fresh blood or frozen PBMCs. If derived from fresh blood, CD8 + T cells (about 15 ~ 30% of PBMCs) are more than 95% viability. If derived from frozen PBMCs, CD8 + T cells (about 10 ~ 25% of PBMCs) are more than 90% viability. Critical: Keep the magnet and tube inverted for 2-3 seconds, then return upright. Don't shake or wipe off any drops that may remain hanging from the tube orifice. j. Centrifuge the purified CD8 + T cells at 400 × g for 5 minutes at 4°C k. Remove supernatant and resuspend the CD8 + T cells in the desired volume of primary T cell medium Time: ~7 days Once the human CD8 + T cells have been isolated in step 10, they will be stimulated in a primary culture in order to induce the production of specific CD8 + T cells and cytokines. Critical: Mitomycin C -To get higher solubility, please warm the tube at 37°C and shake it in an ultrasonic bath for a while. a. Harvest T2-A2 cells from T-75 cell culture flasks by agitation and aspiration using a 10 mL serological pipette, or equivalent. Cells are then transferred to a fresh 15 mL Falcon. b. Centrifuge at 400 × g for 5 minutes at 4°C c. Discard the supernatant and resuspend cells in complete IMDM to a final concentration of approximately 1-2 × 10 6 cells/mL d. Transfer the T2-A2 cells in 2 mL/well into the 6-well plate, add mitomycin C (20 µg/mL) per well, and incubate at 37°C with 5% CO2 for 30 minutes e. Wash twice with PBS and centrifuge at 400 × g for 5 minutes at 4°C Note: The solubility of mitomycin C in DMSO is >16.7mg/mL. To get higher solubility, warm the tube at 37°C and shake it in an ultrasonic bath for a while. Stock solution can be stored foil wrapped below -20℃ for for up to 6 months. CFSE is a fluorescent dye with cellular permeability. It is covalently coupled with intracellular molecules, especially lysine residues and other amine sources, through its succinimide group. The binding of CFSE to cells is stable. It has no toxicity and will not alter the viability of labeled cells. CFSE persists in cells for 24 hours after labeling, thus is suitable for long term detection of labeled cells (Xiao-Qi et al., 2005) . In the process of cell division and proliferation, its fluorescence intensity decreases gradually with the cell division. The labeled fluorescence can be equally distributed to the two daughter cells, so their fluorescence intensity is half of the parental cells. Critical: CFSE -Freshly prepared or make small aliquots and store at -80°C for up to 2 years. Note: The concentration mentioned here is safe (≤ 5 µM ). However, high concentration of CFSE (FITC) might toxic to T cells. a. The CFSE stock solution (5 mM) in DMSO is diluted to a final concentration of 5 µM in PBS with a total volume of 1 mL b. 2-4 × 10 8 T2-A2 cells are resuspended with 1 mL PBS, mixed with 1μL 5 mM CFSE ( final concentration is 5 μM ), and incubated at 37°C, 5% CO2 for 30 minutes with agitation c. The labeling reaction is stopped for 10 minutes by adding 9 mL complete IMDM d. The CFSE labeled cells are washed twice with PBS and recounted, and the cell concentration is adjusted to 5 × 10 6 cells/mL in serum-free IMDM Note: To get higher solubility, warm the tube at 37℃ and shake it in an ultrasonic bath for a while. 14. Peptide screening in T2A2 cells To validate the predicted epitopes, first check if they can be presented by HLA-A2 on the antigen presenting cells. T2A2 is an antigen-presenting cell lacking antigen peptide transporter and expressing HLA-A2 on the cell surface. The peptide-MHC complex would be more stabilized if the epitopes bind with HLA-A2 suitably. a. The candidate peptides (Table 1) c. Discard the supernatant and resuspend cells in primary T cell medium to a final concentration of approximately 2.5 × 10 6 cells/mL d. 0.5 × 10 6 CD8 + T cells isolated from healthy donors and 0.5 × 10 6 peptide loaded T2-A2 cells are mixed and seeded into 96-well plates with 200 µL/well. Add 1 μg/mL anti-CD28 antibody and 50 IU/mL IL-2 into each well, and incubate at 37°C, 5% CO2 e. Every two days, 50 µL old medium is carefully taken along the 96-well plate wall and discarded, and 50 µL fresh T cell culture medium containing 50 IU/mL IL-2 and 20 μM mixed peptide is added Note: When transfer the 96-well plate from the incubator, avoid shaking and carefully move it out of the incubator to prevent the cells from floating on the surface of the medium. f. The T cell activation marker CD69 and tetramer specific CD8 + T cells are evaluated after 16 hours and 7 days, respectively 16. Cell-Surface staining with APC anti-human CD69 CD69 is transiently expressed on activated leukocytes including T, B, and NK cells. CD69 is involved in early events of lymphocyte, platelet, and monocyte activation, and plays a role in redirected lysis mediated by activated NK cells. Note: The T cell activation marker CD69 was evaluated after 16 hours. a. Transfer the 96-well plates from the incubator to the hood. Mix the cells in each well and transfer 30 uL cell (1× 10 6 cells) suspension into 1.5 mL microcentrifuge tubes b. Add 5 µL Human TruStain FcX™ per million cells in 100 µL staining volume, mix and incubate at 25°C for 10 minutes Note: There is no need to wash cells between these blocking and immunostaining steps. Critical: When perform MHC tetramer staining with anti-CD8 antibody in flow cytometry, you need to choose correct CD8 clones to gain the best results. A wrong CD8 clone may lead to undesired reactions on MHC tetramer binding to the TCR, either enhancing or reducing tetramer reaction (Campanelli et al., 2002 ) . We strongly recommend clones T8, Hit8a or MCD8 for human MHC tetramer staining . Also make sure the correct protocol is followed. Time: ~8 hours Activated cell populations can be generated from in vitro-stimulated cultures or from in vivo-stimulated tissues (e.g., antigen-specific activation). The Leukocyte Activation Cocktail, with BD GolgiPlug™ is a ready-to-use polyclonal cell activation mixture including the phorbol ester, a calcium ionophore (Ionomycin), the protein transport inhibitor BD GolgiPlug™ (Brefeldin A) and Phorbol 12-Myristate 13-Acetate (PMA). Primary cytokine responses by T cells can be induced with this mixture. Since Brefeldin A blocks the intracellular protein transport processes, the produced cytokines will be localized in the rough endoplasmic reticulum of the cytokine producing cells. Thus, these cells are readily detected by immunofluorescent staining and flow cytometric analysis due to the accumulation of the increased expression of cytokines. 18. Cell-Surface staining with APC anti-human CD8 a. On day 7, quickly thaw the cocktail in a water bath at 37°C and add 2 µL Leukocyte Activation Cocktail to 1 mL cell culture (e.g., ~10 6 cells/mL) and mix thoroughly b. Culture in CO2 incubator at 37°C for 6 hours Critical: It is suggested not to keep Leukocyte Activation Cocktail, with BD GolgiPlug in a cell culture for more than 12 hours. Note: Store product at -80°C before use or for long-term storage. c. Harvest cells from each well into 1.5 mL microcentrifuge tubes and centrifuged at 300 × g for 5 minutes at 4°C d. Discard the supernatant and resuspend each pellet in 100 µL cold cell staining buffer by gentle swirling e. It is recommended to add 5 µL of Human TruStain FcX™ per million cells in 100 µL staining volume, mix and incubate at 25°C for 10 minutes f. Add 2 µL APC labeled human CD8 + , mix and incubate in the dark for 30 minutes at 4°C g. Wash once with at least 1.5 mL cell staining buffer by centrifugation at 300 × g for 5 minutes at 4°C Note: Some antibodies to surface markers of natural cells may not recognize fixed/denatured antigens. Therefore, it is suggested to stain cell surface antigens with live and unfixed cells before cell fixation/permeabilization and intracellular staining. Stain the cell surface antigens as described in step 18, then fix cells in 0.5 mL/tube Fixation Buffer in the dark for 20 minutes at 25°C c. Resuspend the fixed and intracellular labeled cells with 0.2 mL cell staining buffer and perform flow cytometric analysis, representative data and a gating strategy are shown in ( Figure 4B ) Note: Set photomultiplier tube voltage and compensation using cell surface staining controls. Set quadrant markers based on isotype controls, unstained cells or blocking controls. To perform appropriate flow cytometric analysis, the cells stained with this method should be examined by optical microscope and/or flow light scattering mode to confirm that they are well dispersed. Bivariate dot plots or probability contour plots can be generated by data analysis to show the frequencies and patterns by which individual cells demonstrate co-expression of a certain level of cell surface antigen and intracellular cytokine proteins. The function of the immune responses against SARS-CoV-2 is urgently needed for understanding the pathogenesis of the disease and its vaccine development. CD8 + T cells are critical for virus clearance and induce long lasting protection in the host. Here we identified specific HLA-A2 restricted T cell epitopes in the protein of SARS-CoV-2. Epitope peptides were confirmed to bind with HLA-A2 and presented by antigen presenting cells to induce host immune responses. In addition, these epitopes could activate and generate epitopespecific T cells in vitro, and those activated T cells showed cytotoxicity to target cells (T2-A2 cells). Our data strongly indicated that mutant epitopes in SARS-CoV-2 variant caused deficiency in antigen presentation and CD8 + T cell immune responses. It is required to rebuild a new CD8 + T cell immune response for variant SARS-CoV-2. One of the limitations is the usage of sorted CD8 + T cells rather than total PBMCs. Since the proportion of T cells in PBMCs is relatively low, the proportion of activated specific CD8 + T cells is even less. Furthermore, our study focused on HLA-A*02 restricted epitopes currently, and other HLA class I allotype restricted CD8 + T cells specific epitopes should be included for a broader understanding of SARS-CoV-2 induced immune responses, which shall be addressed in further studies. Low percentage of specific CD8 + T cells generation after stimulation (steps 15-17). In this work, 50 µL fresh T cell culture medium containing 50 IU/mL IL-2 and 20 μM mixed peptide ( Figure 5 ) (Positive control (Influenza A M1 peptide M58-66 GILGFVFTL) and negative control (EBV virus E416-424 IVTDFSVIK) peptides) was added every two days. Another solution is to extend the stimulation time appropriately 1-3 days. A wrong anti-CD8 antibody clone may lead to undesired reactions on MHC tetramer binding to the TCR, either enhancing or reducing tetramer reaction (steps 17). When perform MHC tetramer staining with anti-CD8 antibody in flow cytometry, you need to choose correct anti-CD8 antibody clone to gain the best results. We strongly recommend clones T8, Hit8a or MCD8 for human MHC tetramer staining. Also make sure the correct protocol is followed. J o u r n a l P r e -p r o o f Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T cell activation Identification of HLA-A2 restricted CD8+ T cell epitopes in SARS-CoV-2 structural proteins Carboxyfluorescein Diacetate Succinimidyl Ester Fluorescent Dye for Cell Labeling Resource Availability Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Guobing Chen (guobingchen@jnu.edu.cn) The corresponding tetramers may be obtained from the research group of Guobing Chen, Jinan University, China. No datasets were generated using this protocol.